LGA
REGN icon

Lebenthal Global Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Lebenthal Global Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
532
-30
-5% -$20.4K 0.04% 179
2026
Q1 		$434K Sell
562
-79
-12% -$60.5K 0.06% 163
2025
Q4 		$495K Buy
+641
New +$435K 0.08% 149

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Lebenthal Global Advisors's REGN Position: Q2 2026 in Review

Lebenthal Global Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 5.3% in Q2 2026, selling an estimated $20.4K and leaving 532 shares worth $332K. The position accounts for 0.04% of the portfolio, ranked #179.

Lebenthal Global Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $495K in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Lebenthal Global Advisors held 532 shares of Regeneron Pharmaceuticals worth $332K as of Q2 2026.
  • Lebenthal Global Advisors sold 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Regeneron Pharmaceuticals made up 0.04% of Lebenthal Global Advisors's portfolio in Q2 2026, its #179 holding.
  • Lebenthal Global Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Lebenthal Global Advisors's Regeneron Pharmaceuticals position peaked at $495K in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Lebenthal Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.